Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 20;11:784777. doi: 10.3389/fonc.2021.784777

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Tian, Han, Huang, Li and Pang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Paclitaxel-resistance was enhanced by gp96 in BC cells through degrading p53. (A, B) Upregulation of gp96 increased paclitaxel-resistance in PS-BC cells, as determined by MTT assay. (C) Overexpressed gp96 restrained paclitaxel-induced cell apoptosis in PS-BC cells (related with Figures S3A, B ). (D, E) MTT assay results evidenced that silencing gp96 increased paclitaxel-sensitivity in PR-BC cells. (F) FCM results supported that knockdown of gp96 enhanced the promoting effects of paclitaxel on cell apoptosis in PR-BC cells (related with Figures S3C, D ). The (G) mRNA and (H, I) protein levels of p53 in PS-BC cells were respectively examined by Real-Time qPCR and Western Blot analysis. (J, K) The inhibition rate of paclitaxel treatment on PS-BC cells were examined by MTT assay. Note: OE-gp69 indicated gp96 overexpression. *P < 0.05, **P < 0.01.